Nimble Science Expands Network of Global Certified Service Partners: Welcomes SeqBiome

Calgary, Canada – January 28, 2025

2025.01.28 Nimble SeqBiome.pdf

Download PDF • 165KB

Nimble Science, the pioneer of enabling at-home intestinal fluid biopsies, announced today the expansion of its Certified Service Partner network to include SeqBiome – a world-leading contract microbiome research company, providing technical and scientific services to researchers in the Pharma, Food, and Nutrition industries. This strategic move aims to leverage the expertise and reach of diverse partners to enhance customer experience and support the full potential of Nimble’s SIMBA GI Health Platform to advance health research.  

SeqBiome will join the network that currently includes NIZO Food Research in the Netherlands and Cmbio™ located in both the US and Denmark as Certified Service Providers for Nimble Science’s innovative platform, providing clients access to high-quality, multi-omic data from the small intestine to advance microbiome research and support innovative advances in personalized healthcare. Joseph Wang, CTO of Nimble Science emphasizes the value the Certified Service Providers bring: “The SIMBA™ Capsule is designed to maintain the highest quality of small intestinal samples, contaminant-free and preserved from the point of collection. For clients, service delivery with Certified Service Partners ensures the data quality is maintained and the data is analyzed with the greatest expertise, incorporating the latest insights offered by the Platform.”

David Corr, CEO of SeqBiome expressed his enthusiasm for the opportunity to bring Nimble’s novel service platform to their customers: "SeqBiome is thrilled to partner with Nimble Science on the launch of their SIMBA GI Health Platform. With a proven track record in microbiome research, SeqBiome continues to enhance its services through innovative partnerships for our customers’ benefit. We look forward to collaborating with Nimble and exploring the exciting projects this initiative will bring. "

The small intestine plays a pivotal role in nutrient absorption, immune function, and metabolic regulation. However, due to its inaccessibility, research has often relied on fecal samples as proxies for gut health—providing only partial insights. Nimble's SIMBA™ Capsule overcomes this limitation by collecting uncontaminated fluid biopsies directly from the small intestine. It uses a proprietary mechanism that shields samples from contamination and preserves nucleic acids during their journey through the digestive tract, ensuring highly accurate and reliable data for analysis. The fluid samples are ideal for multi-omic analyses, including metagenomics, metabolomics, and proteomics, enabling researchers to explore microbial activities and metabolite production with exceptional precision. The ability to accurately interrogate the small intestinal environment has the potential to significantly impact various sectors, including pharmaceuticals, nutrition, diagnostics and consumer health.

Sabina Bruehlmann, CEO of Nimble Science, highlighted the importance of working with global industry leaders in delivering the SIMBA GI Health Platform: “At-home collection of endoscopic quality intestinal fluid biopsies can transform GI health research, with overwhelming possibilities. Ensuring our products are delivered by industry leaders with expertise to support the collection and analysis of the highest quality data is integral to ensuring that it brings the greatest impact.”

SIMBA™ Capsules are available via a Platform Service model, enabling users to evaluate the small intestine in direct response to their research query, whether it is a particular disease status or intervention response.  The Platform further supports this novel approach with data quality indexing and access to valuable insights derived from a growing repository of matched metagenomic data sets from healthy and disordered small intestinal samples. Streamlining the delivery of this novel data platform through a certified network of service partners will enable the widest possible reach of researchers, facilitating their exploration of this new frontier and maximizing the potential for advancements in health.

About Seqbiome

Seqbiome, a spin-out from world leading research centre in Ireland, APC Microbiome, provides pre-clinical and clinical research services, specifically, custom microbiome testing services for academia, food, pharma, and nutraceutical researchers globally.  The Seqbiome solution is is uniquely “end-to-end” and includes Consulting services, Next Generation Sequencing (NGS) and other molecular testing, Bioinformatics services, and generating high quality, custom reports of study outcomes.  The company has developed high-quality in house workflows and protocols across a range of sample and microbiomes and, through key partnerships, the company can provide broader, multi-omics services. 

About Nimble Science

Nimble Science is a precision medicine company providing a multi-omic data platform to advance healthcare innovation. Its SIMBATM Capsule enables unparalleled access to the microenvironment of the small intestine. Nimble's mission is to revolutionize health innovation by empowering researchers and clinicians with transformative tools to unlock new possibilities in diagnostics, therapeutics, and beyond. The company is supported by leading life science investors, including Fusion Fund, Seventure Partners, Joyance Partners and Ki Tua Fund, who recognize the transformative potential of Nimble's groundbreaking approach to health product innovation and precision medicine.

For media inquiries:

Seqbiome

David Corr, CEO

info@seqbiome.com

Nimble Science

1.866.493.4633

Sabina Bruehlmann, CEO

sabina@nimblesci.com